

Charlie Kim

Partner



ckim@cooley.com

+1 858 550 6049

San Diego

Capital Markets
Public Companies
Emerging Companies
Debt Finance
Life Sciences
Technology
Ecommerce + Marketplace
Food and Beverage
Retail and Consumer Products

Charlie Kim is co-chair of Cooley's global capital markets practice group. He is a nationwide leader in capital markets transactions and has worked on 200+ successfully completed public company securities offerings since 2019 (including Uber's \$8.1 billion IPO and 3 of the 5 biggest biotechnology IPOs to date). Charlie focuses on representing US and non-US issuers, investment banking firms and venture capital firms in public offerings and private placements of equity and debt securities. He is also co-chair of the American Pacific Islander Attorney Affinity Group as well as a member of the DEI Advisory Council at Cooley.

Charlie has been consistently recognized by many legal publications, including:

- Chambers USA: Band 1 for Capital Markets – California and Nationwide
- LMG Life Sciences 2023 Corporate Attorney of the Year
- The Legal 500: Leading Lawyer – Capital Markets: Equity Offerings
- Daily Journal: Top 100 Lawyer across all specialties in California and recipient of the California Lawyer Attorneys of the Year Award
- The Daily Transcript: San Diego Top Attorney
- Law360: MVP of the Year – Capital Markets
- Thomson Reuters: Super Lawyer – Southern California and San Diego

Charlie has worked on securities offerings by leading innovative companies across industries, including: AbCellera, Accelerate, ACELYRIN, Acutus, Advaxis, Aerohive, Agenus, Akari, Akcea, Akero, Allogene, Alteryx, Ambix, Amylin, Anadys, AnaptysBio, Angion, Annexon, Anthera, Apogee, Applied Molecular Transport, Arcadia, Arcus, Arcutis, Ardea, Arena, Aridis, Ascendis, ASLAN, Athira, Audentes, Avidity, Ballast Point Brewing & Spirits, Biomea, Boundless Bio, Cadence, CARGO, Castlight, Cerus, CG Oncology, Cidara, Clorox, Corcept, Crinetics, Cue Health, Cyan, Cytari, Day One, Dermira, Design, DICE, Doximity, Dynavax, eBay, EHang, Eidos, Elevation Oncology, Entropic, Erasca, Exagen, Evofem, Fangdd, FIGS, FireEye, Five Prime, Gemphire, Genomatica, Global Blood, Gossamer, Gracell, Graphite Bio, Gritstone, Guardant Health, Halozyme, Health Catalyst, Healthcare Royalty, HealthEquity, Horizon, IGM, Ignyta, Immune Design, IMV, Inhibrx, Inovio, Insys, Invitae, Ionis, Janux, Jazz Pharmaceuticals, Kamada, Kinate, Kite Pharma, Kronos, Landry's, LifeLock, Limelight, Livongo, Longboard, Lyell, MannKind, Medallia, MethyGene, Metropark, MindBody, Minerva, Mirati, NantHealth, NantKwest, Nektar, Neon, Neumora, Neurocrine, ObsEva, Olink, Ooma, Optimer, ORIC, Otonomy, Pernix, Phathom, Poseida, PRA Holdings, PROCEPT, Progressive Gaming, ProNAi, ProQR, Proto Labs, Qualtrics, Quidel, Radiant Systems, Rani, Raptor, RayzeBio, Reata, Receptos, Regulus, ReSearch Pharmaceutical Services, Sana, Sangamo, Santarus, Savara, Seattle

Genetics, Senomyx, Sequenom, ShockWave, Sierra, Silverback, Singular Genomics, Somaxon, Strongbridge, Structure, Surface Oncology, Sutro, Syndax, Tableau Software, Tabula Rasa, Taiwan Liposome Company, Tangoe, Tarsus, Third Harmonic, TRACON, Treace, Tricida, Trius, TriVascular, Uber Technologies, Vaxcyte, Ventyx Biosciences, Verenum, Verona, Vical, ViewRay, Viking, Vir, Vital Therapies, Vor, Xencor, Xenon, XenoPort, Zealand Pharma, Zentalis, Zogenix, Zscaler, Zymeworks, 4D Molecular Therapeutics, 10x Genomics and 89bio.

Charlie regularly represents all the leading investment banks, including: Barclays, BMO, BofA Securities, Canaccord, Cantor, Citigroup, Credit Suisse, Deutsche Bank, Evercore, Goldman Sachs, Guggenheim, H.C. Wainwright, Jefferies, JMP Securities, J.P. Morgan, Lazard, Leerink, Morgan Stanley, Needham, Oppenheimer, Piper Sandler, Raymond James, RBC, Stifel, SunTrust, TD Cowen, Truist, UBS, Wedbush, Wells Fargo and William Blair.

Charlie also represented Jeff Moorad/JSM Acquisition in connection with their acquisition of the San Diego Padres Major League Baseball franchise.

Charlie is a regular panelist at numerous IPO preparation conferences every year. He has also been a featured panelist in the Practising Law Institute's national "How to Prepare an Initial Public Offering" seminar, the Securities Regulation Institute's national panel on "Key issues in Capital Formation," the Asia and US Life Sciences Roadshow, and the BFC Global Healthcare Investment Conference focused on Asian healthcare companies and investors. He has been a multi-year member of Law360's Capital Markets Editorial Advisory Board. Charlie has also served as a regular guest lecturer at the Entrepreneurship Clinic and in a course entitled "High Tech Start-Ups" at the University of San Diego School of Law. Charlie also contributed to the widely read textbook entitled "The Entrepreneur's Guide to Business Law" as well as to Cooley's IPO handbooks.

Education

New York University School of Law
JD, 2000

Princeton Theological Seminary
MDiv, 1997

University of Michigan, Ann Arbor
BA, 1994

Admissions & Credentials

California

New York

Court Admissions

US District Court for the Southern District of California

Rankings & Accolades

Chambers USA: Band 1 for Capital Markets: Debt & Equity – California (2021 – 2023)

Chambers USA: Band 1 for Capital Markets: Debt & Equity: Western United States – Nationwide (2020 – 2023)

The Legal 500 US: Leading Lawyer in Capital Markets: Equity Offerings (2023)

Daily Journal: Top 100 Lawyer across all specialties in California and recipient of the California Lawyer Attorneys of the Year Award

The Daily Transcript: San Diego Top Attorney

Law360: MVP of the Year – Capital Markets

Thomson Reuters: Super Lawyer – Southern California and San Diego

Memberships & Affiliations

American Bar Association

Council of Korean Americans

New York State Bar Association

San Diego County Bar Association